{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 109 of 169', 'The 4 hypotheses of primary interest for maintenance treatment will be tested sequentially', 'with the next hypothesis in the sequence only being tested if the previous one was significant.', 'The multiple testing procedure planned to control the overall type 1 error rate for the trial is', 'described in detail in Section 12.3.4. The maintenance endpoints will be evaluated in the', 'following order:', 'No difference between Q2W and placebo for IGA 0/1 at Week 52.', 'No difference between Q2W and placebo for EASI75 at Week 52.', 'No difference between Q4W and placebo for IGA 0/1 at Week 52.', 'No difference between Q4W and placebo for EASI75 at Week 52.', 'For the IGA 0/1 endpoint, the analysis will be based on the subjects in the maintenance', 'analysis set who obtained an IGA of 0/1 at Week 16 without rescue medication. For the', 'EASI75 endpoint, the analysis will be based on the subjects in the maintenance analysis set', 'who obtained an EASI75 at Week 16 without rescue medication.', 'For each endpoint (IGA 0/1 and EASI75 at Week 52) the estimated response rates and', 'corresponding 95% CIs, and the pairwise treatment differences will be presented. The', 'difference in response rates between treatment groups will be analysed using the', 'Cochran-Mantel-Haenszel test stratified by region. The null hypotheses of no difference in', 'response rates will be tested against the two-sided alternative that there is a difference.', 'Sensitivity analysis for the maintenance estimand', 'In a sensitivity analysis, data missing at Week 52 for subjects who did not receive rescue', 'medication, did not transfer to open-label and did not withdraw from the trial due to AE or', 'lack of efficacy will be imputed using LOCF.', 'Pooled analyses across both LP0162-1325 and LP0162-1326', 'In order to achieve more precise estimates of clinical response within treatment groups in the', 'maintenance period, analyses of IGA 0/1 and EASI75 at Week 52 will be performed on', 'pooled data from the 2 trials LP0162-1325 and LP0162-1326. For each endpoint (IGA 0/1', 'and EASI75 at Week 52) the estimated response rates and corresponding 95% CIs and the', 'pairwise treatment differences will be presented. The difference in response rates between', 'treatment groups will be analysed using the Cochran-Mantel-Haenszel test stratified by region', 'within trial. The pooled analyses will only be presented in marketing authorisation', 'applications.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 110 of 169', '12.3.6.2 Analysis of other maintenance endpoints', '12.3.6.2.1 Time to relapse', 'The following 2 types of relapse will be considered and analysed:', 'Relapse according to IGA: first assessment of an IGA>2 or initiation of rescue', 'medication after initiation of maintenance treatment among subjects in the', 'maintenance analysis set who obtained an IGA 0/1 at Week 16 without rescue', 'medication.', 'Relapse according to EASI75: first time of not achieving EASI75 or initiation of', 'rescue medication after initiation of maintenance treatment among subjects in the', 'maintenance analysis set who obtained EASI75 at Week 16 without rescue medication.', 'Kaplan-Meier curves of time to relapse will be estimated and presented by treatment for the', 'maintenance analysis set. In a supplementary exploratory analysis, tralokinumab Q2W vs.', 'placebo and tralokinumab Q4W VS. placebo will be compared using a log-rank test stratified', 'by region.', 'Subjects leaving the trial without meeting the relapse criteria will be censored at the date of', 'the last assessment visit.', '12.3.6.2.2 Continued treatment for non IGA responders', 'The number of responders according to IGA 0/1 at Week 52 will be tabulated for the subgroup', 'of subjects in the maintenance analysis set who are re-randomised meeting the EASI75', 'criterion but not the IGA 0/1 criterion at Week 16.', '12.3.6.2.3 Supportive maintenance', 'To support the maintenance objective, the response IGA 0/1 or EASI75 at Week 52 will be', 'presented and analysed as described above for the primary analysis of the maintenance', 'estimand for subjects in the maintenance analysis set who did not receive rescue medication', 'prior to Week 16.', '12.3.7 Analysis of safety', 'The analyses of safety will be based on the safety analysis sets. The reporting of safety data', 'will be presented separately for the initial treatment, the maintenance treatment, and the', 'open-label treatment.', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}